Igarashi et al., 2022 - Google Patents
Identification and quantitative structure–activity relationship assessment of trace chemical impurities contained in the therapeutic formulation of [64Cu] Cu-ATSMIgarashi et al., 2022
- Document ID
- 3620824562316203754
- Author
- Igarashi C
- Matsumoto H
- Takahashi M
- Hihara F
- Tachibana T
- Zhang M
- Kurihara H
- Higashi T
- Yoshii Y
- Publication year
- Publication venue
- Nuclear Medicine and Biology
External Links
Snippet
Abstract Background [64 Cu] Cu-diacethyl-bis (N 4-methylthiosemicarbazone)([64 Cu] Cu- ATSM) is a radioactive hypoxia-targeting therapeutic agent, and the efficacy and safety of [64 Cu] Cu-ATSM in the treatment of malignant brain tumors are evaluated in clinical trials …
- 239000012535 impurity 0 title abstract description 95
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0493—Steroids, e.g. cholesterol, testosterone
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tshibangu et al. | Automated GMP compliant production of [18F] AlF-NOTA-octreotide | |
| McNeil et al. | Production, purification, and radiolabeling of the 203Pb/212Pb theranostic pair | |
| Gracheva et al. | Production and characterization of no-carrier-added 161Tb as an alternative to the clinically-applied 177Lu for radionuclide therapy | |
| Loveless et al. | Photonuclear production, chemistry, and in vitro evaluation of the theranostic radionuclide 47Sc | |
| US9874550B2 (en) | Method for the quantification of 227AC in 223RA compositions | |
| Fonslet et al. | 135La as an Auger-electron emitter for targeted internal radiotherapy | |
| Ferrier et al. | Thorium chelators for targeted alpha therapy: Rapid chelation of thorium‐226 | |
| Sinenko et al. | 213Bi production and complexation with new picolinate containing ligands | |
| Pozzi et al. | Radiopharmaceutical chemistry of targeted radiotherapeutics, part 1: effects of solvent on the degradation of radiohalogenation precursors by 211At α-particles | |
| Pozzi et al. | Radiopharmaceutical chemistry of targeted radiotherapeutics, part 2: radiolytic effects of 211At α-particles influence N-succinimidyl 3-211At-astatobenzoate synthesis | |
| McNeil et al. | A simple and automated method for 161Tb purification and ICP-MS analysis of 161Tb | |
| Favaretto et al. | Terbium-149 production: a focus on yield and quality improvement towards preclinical application | |
| Igarashi et al. | Identification and quantitative structure–activity relationship assessment of trace chemical impurities contained in the therapeutic formulation of [64Cu] Cu-ATSM | |
| Kraihammer et al. | Improved quality control of [177Lu] Lu-PSMA I&T | |
| Nishinaka et al. | Preparation of no-carrier-added 211At solutions by a simple dry distillation method in the 209Bi (4He, 2n) 211At reaction | |
| Liu et al. | Development of an automated production process of [64Cu][Cu (ATSM)] for positron emission tomography imaging and theranostic applications | |
| Verduyckt et al. | Identity confirmation of 99mTc-MAG3, 99mTc-Sestamibi and 99mTc-ECD using radio-LC-MS | |
| Søndergaard et al. | Production of 67Cu at a biomedical cyclotron via 70Zn (p, α) 67Cu reaction and its evaluation in a preclinical study using small animal SPECT/CT | |
| Aliev et al. | Separation of 167Tm, 165Er and 169Yb from erbium targets irradiated by 60 MeV alpha particles | |
| Blok et al. | Good practices for the automated production of 18F-SiFA radiopharmaceuticals | |
| Grundmane et al. | Novel dibutyl ether resin for the purification of the auger emitter antimony-119 from tin targets | |
| Jószai et al. | Recommendations for selection of additives for stabilization of [18F] FDG | |
| Lee et al. | Medical radioisotope 89Zr production with RFT-30 cyclotron | |
| genannt Koers et al. | Production of Co-58m in a siphon-style liquid target on a medical cyclotron | |
| Vanderghinste et al. | An efficient HPLC method for the analysis of isomeric purity of technetium-99m-exametazime and identity confirmation using LC–MS |